Article Text

other Versions

Download PDFPDF
GI adverse effects associated with GLP-1 agonists for weight loss

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Key learning points

  • There has been a rapid increase in the use of glucagon-like peptide (GLP-1) receptor agonists for weight loss.

  • Studies have reported increased risks of adverse gastrointestinal (GI) events in people with diabetes treated with GLP-1 agonists.

  • A cohort study found that GLP-1 agonists used for weight loss are associated with increased risk of pancreatitis, bowel obstruction and delayed stomach emptying compared with bupropion-naltrexone.

A cohort study highlighted increased risks of serious gastrointestinal adverse events associated with glucagon-like peptide (GLP-1) receptor agonists used for weight loss compared with bupropion-naltrexone.1

Overview

This cohort study used prescription and diagnostic data for 16 million patients in the USA from 2006 to 2020 to examine gastrointestinal events associated with the use of …

View Full Text

Footnotes

  • Contributors DTB Team.

  • Provenance and peer review Commissioned; internally peer reviewed.